ES2186576A1 - Acido 2-hidroxioleico para utilizar como medicamento. - Google Patents

Acido 2-hidroxioleico para utilizar como medicamento.

Info

Publication number
ES2186576A1
ES2186576A1 ES200102269A ES200102269A ES2186576A1 ES 2186576 A1 ES2186576 A1 ES 2186576A1 ES 200102269 A ES200102269 A ES 200102269A ES 200102269 A ES200102269 A ES 200102269A ES 2186576 A1 ES2186576 A1 ES 2186576A1
Authority
ES
Spain
Prior art keywords
hydroxyoleic acid
medicaments
production
similar compounds
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200102269A
Other languages
English (en)
Other versions
ES2186576B1 (es
Inventor
Ruiz Pablo Vicente Escriba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de les Illes Balears
Original Assignee
Universitat de les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200102269A priority Critical patent/ES2186576B1/es
Application filed by Universitat de les Illes Balears filed Critical Universitat de les Illes Balears
Priority to PCT/ES2002/000475 priority patent/WO2003030891A1/es
Priority to CA2463348A priority patent/CA2463348C/en
Priority to CNB028201132A priority patent/CN100471492C/zh
Priority to US10/488,726 priority patent/US20050014831A1/en
Priority to MXPA04003255A priority patent/MXPA04003255A/es
Priority to BRPI0213165A priority patent/BRPI0213165B8/pt
Priority to AT02783094T priority patent/ATE322261T1/de
Priority to CN2008100917937A priority patent/CN101259121B/zh
Priority to PT02783094T priority patent/PT1435235E/pt
Priority to JP2003533923A priority patent/JP4737931B2/ja
Priority to RU2004114229/15A priority patent/RU2310445C2/ru
Priority to CN2008100917941A priority patent/CN101259122B/zh
Priority to DE60210488T priority patent/DE60210488T2/de
Priority to EP02783094A priority patent/EP1435235B1/en
Priority to ES02783094T priority patent/ES2261752T3/es
Publication of ES2186576A1 publication Critical patent/ES2186576A1/es
Publication of ES2186576B1 publication Critical patent/ES2186576B1/es
Application granted granted Critical
Priority to US12/082,938 priority patent/US7851507B2/en
Priority to US12/939,641 priority patent/US8778995B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ácido 2-hidroxioleico para utilizar como medicamento. La invención se refiere al ácido 2-hidroxioleico como agente antitumoral, como agente con actividad hipotensora y como agente que permite inducir una reducción del peso corporal. El ácido 2- hidroxioleico tiene aplicación como agente regulador de la actividad de proteínas G, así como de las entidades moleculares de su vía de transducción. También se refiere a la utilización del ácido 2-hidroxioleico para la fabricación de medicamentos destinados al tratamiento del cáncer, de enfermedades cardiovasculares y de sujetos con obesidad.
ES200102269A 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento. Expired - Fee Related ES2186576B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.
CN2008100917941A CN101259122B (zh) 2001-10-11 2002-10-09 羟油酸及相关化合物在制备药物中的应用
CA2463348A CA2463348C (en) 2001-10-11 2002-10-09 Use of hydroxyoleic acid and related compounds in the manufacture of drugs
US10/488,726 US20050014831A1 (en) 2001-10-11 2002-10-09 Use of hydroxyoleic acid and similar compounds in the production of medicaments
MXPA04003255A MXPA04003255A (es) 2001-10-11 2002-10-09 Utilizacion de acido hidrocioleico y compuestos analogos del mismo en la fabricacion de medicamentos.
BRPI0213165A BRPI0213165B8 (pt) 2001-10-11 2002-10-09 uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas
AT02783094T ATE322261T1 (de) 2001-10-11 2002-10-09 Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten
CN2008100917937A CN101259121B (zh) 2001-10-11 2002-10-09 羟油酸及相关化合物在制备药物中的应用
DE60210488T DE60210488T2 (de) 2001-10-11 2002-10-09 Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten
JP2003533923A JP4737931B2 (ja) 2001-10-11 2002-10-09 医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用
PCT/ES2002/000475 WO2003030891A1 (es) 2001-10-11 2002-10-09 Utilizacion del acido hidroxioleico y compuestos analogos del mismo en la fabricacion de medicamentos
CNB028201132A CN100471492C (zh) 2001-10-11 2002-10-09 羟油酸及相关化合物在制备药物中的应用
PT02783094T PT1435235E (pt) 2001-10-11 2002-10-09 Utilizacao de acido hidroxioleico e compostos semelhantes na producao de medicamentos
EP02783094A EP1435235B1 (en) 2001-10-11 2002-10-09 Use of hydroxyoleic acid and similar compounds in the production of medicaments
ES02783094T ES2261752T3 (es) 2001-10-11 2002-10-09 Uso del acido hidroxioleico y compuestos similares en la produccion de medicamentos.
RU2004114229/15A RU2310445C2 (ru) 2001-10-11 2002-10-09 Применение гидроксиолеиновой кислоты и родственных соединений при производстве лекарственных средств
US12/082,938 US7851507B2 (en) 2001-10-11 2008-04-15 Use of hydroxyoleic acid and related compounds in the manufacture of drugs
US12/939,641 US8778995B2 (en) 2001-10-11 2010-11-04 Use of hydroxyoleic acid and related compounds in the manufacture of drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.

Publications (2)

Publication Number Publication Date
ES2186576A1 true ES2186576A1 (es) 2003-05-01
ES2186576B1 ES2186576B1 (es) 2004-09-16

Family

ID=8499164

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200102269A Expired - Fee Related ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.
ES02783094T Expired - Lifetime ES2261752T3 (es) 2001-10-11 2002-10-09 Uso del acido hidroxioleico y compuestos similares en la produccion de medicamentos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02783094T Expired - Lifetime ES2261752T3 (es) 2001-10-11 2002-10-09 Uso del acido hidroxioleico y compuestos similares en la produccion de medicamentos.

Country Status (13)

Country Link
US (3) US20050014831A1 (es)
EP (1) EP1435235B1 (es)
JP (1) JP4737931B2 (es)
CN (3) CN101259121B (es)
AT (1) ATE322261T1 (es)
BR (1) BRPI0213165B8 (es)
CA (1) CA2463348C (es)
DE (1) DE60210488T2 (es)
ES (2) ES2186576B1 (es)
MX (1) MXPA04003255A (es)
PT (1) PT1435235E (es)
RU (1) RU2310445C2 (es)
WO (1) WO2003030891A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
CN101570481B (zh) * 2008-04-30 2012-02-01 上海医药工业研究院 一种多羟基长链脂肪酸及其分离提取方法和在抑制芳香化酶活性中的应用
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
WO2011089265A1 (en) 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
CN101985420B (zh) * 2010-01-29 2014-04-30 苏州润新生物科技有限公司 油酸酯及其制备方法和在制备用于治疗高血压及其并发症的药物中的应用
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
US20140357715A1 (en) * 2012-01-19 2014-12-04 Nippon Suisan Kaisha, Ltd. Anorectic agent
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
AU2013322612B2 (en) * 2012-09-26 2017-06-01 Tangent Reprofiling Limited Modulators of androgen synthesis
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
EP3209637B1 (en) * 2014-10-21 2019-05-08 Universitat de les Illes Balears 2-hydroxy-triacylglycerol compounds for use in treating disease
US10756968B2 (en) 2015-01-26 2020-08-25 Rapid7, Inc. Network resource management devices methods and systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001100A1 (en) * 1992-07-01 1994-01-20 Arch Development Corporation METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61297A (ja) * 1984-06-12 1986-01-06 日本油脂株式会社 オレイン酸の製造法
GB8603621D0 (en) 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
JPS6344843A (ja) * 1986-08-13 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
CN1118218A (zh) * 1995-03-16 1996-03-13 姜训书 松籽油的制作方法及松籽保健食用油
CN1118228A (zh) * 1995-03-16 1996-03-13 姜训书 松籽果酱
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
PT771817E (pt) * 1995-10-30 2003-06-30 Oleoyl Estrone Developments S Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
DE19727636C1 (de) * 1997-06-28 1998-11-19 Rwe Dea Ag Verfahren zur Herstellung von 2-Alkylcarbonsäuren
CN1212867A (zh) * 1997-09-29 1999-04-07 宋凤亭 防治心脑血管疾病的组合物
CA2227706C (en) * 1998-01-21 2010-08-03 Patrick Pageat Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
CA2436536C (en) * 2000-12-23 2008-07-08 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
DE10130491A1 (de) * 2001-06-25 2003-04-17 Heirler Horst Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001100A1 (en) * 1992-07-01 1994-01-20 Arch Development Corporation METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AWAD ATIF, B. et al.: "18:1 n7 fatty acids inhibit growth and decrease inositol phosphorate release in HT-29 cells compared to n9 fatty acids", Cancer Letters, 1995, Vol. 91 (1), pßginas 55-61, ISSN:0304-3835, todo el documento, en particular, resumen. *
DE CATERINA, R. et al.: "The direct effect of injectable cyclosporine and its vehicle, cremophor, on endothelial vascular cell adhesion molecule-1 expression: Ricinoleic acid inhibits coronary artery endothelial activation", Transplantation (Baltimore), (1995), Vol. 60 (3), pßginas 270-275, ISSN:0041-1337, todo el documento. *
SEBASTIANO, B. et al.: "Vaccenic acid feeding increases tissue levels of conjugated linoleic acid and supresses development of premalignant lesions in rat mammary gland", Nutrition and Cancer, 2001, Vol. 41 (1-2), páginas 91-97, ISSN:0163-5581, todo el documento, en particular, página 57, columna 2, líneas 7-9. *

Also Published As

Publication number Publication date
CN101259121A (zh) 2008-09-10
BR0213165A (pt) 2004-09-14
DE60210488D1 (de) 2006-05-18
PT1435235E (pt) 2006-08-31
CN101259122B (zh) 2011-04-06
US20090082446A1 (en) 2009-03-26
BRPI0213165B8 (pt) 2021-05-25
US8778995B2 (en) 2014-07-15
WO2003030891A1 (es) 2003-04-17
CN1688302A (zh) 2005-10-26
ES2261752T3 (es) 2006-11-16
US7851507B2 (en) 2010-12-14
CN101259122A (zh) 2008-09-10
CA2463348A1 (en) 2003-04-17
ATE322261T1 (de) 2006-04-15
DE60210488T2 (de) 2006-12-14
RU2310445C2 (ru) 2007-11-20
EP1435235A1 (en) 2004-07-07
CA2463348C (en) 2011-04-05
JP2005527479A (ja) 2005-09-15
EP1435235B1 (en) 2006-04-05
US20050014831A1 (en) 2005-01-20
ES2186576B1 (es) 2004-09-16
MXPA04003255A (es) 2005-01-25
BRPI0213165B1 (pt) 2018-01-23
CN101259121B (zh) 2011-04-06
RU2004114229A (ru) 2005-04-20
CN100471492C (zh) 2009-03-25
JP4737931B2 (ja) 2011-08-03
US20110136906A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
ES2186576A1 (es) Acido 2-hidroxioleico para utilizar como medicamento.
RS20050361A (en) Novel medicament for the treatment of chronic obstructive pulmonary diseases
ATE479433T1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
CA2793138C (en) Hydroxybenzoate salts of metanicotine compounds
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
HK1090559A1 (en) Immunosuppressant compounds and compositions
TNSN05294A1 (en) Immunosuppressant compounds and compositions
MXPA05012461A (es) Compuestos y composiciones inmunosupresores.
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
WO2008080844A9 (en) Azaspiro derivatives
WO2004052371A3 (en) Cyclic quinoline compounds for use in mch receptor related disorders
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
EP2535329A3 (en) Spiro-piperidine derivatives
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
NO20082127L (no) Antagonister mot interaksjon av PF4 og Rantes
TW200833696A (en) Spiro-piperidine derivatives
MXPA05013596A (es) Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad.
WO2021111377A3 (en) Methods of treating lichen planus using interleukin-17 (il-17) antagonists
ZA200604748B (en) Novel indeno[2,1A]indenes and isoindol[2,1-A]indoles
SE0302666D0 (sv) Novel Compounds

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030501

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2186576B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20220126